Note 10 - Segment Information: Schedule of Segment Reporting Information, by Segment (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 31, 2018	Jan. 31, 2017	Jan. 31, 2018	Jan. 31, 2017
Details
Net revenues - Chinese Medicines	$ 675,927	$ 859,933	$ 2,099,147	$ 2,240,055
Net revenues - Chinese medicine - related party	0	0	0	0
Net revenues - Chinese medicine - Total	675,927	859,933	2,099,147	2,240,055
Net revenues - Stevioside - third party	4,058,336	3,421,023	11,135,229	8,413,018
Net revenues - Stevioside - related party	1,591,329	2,129,371	1,858,709	5,591,740
Net revenues - Stevioside - Total	5,649,665	5,550,394	12,993,938	14,004,758
Net revenues - Total segment and consolidated revenues	6,325,592	6,410,327	15,093,085	16,244,813
Interest income - Chinese Medicines	386	105	742	178
Interest income - Stevioside	(152,055)	(100,363)	(387,670)	(270,334)
Interest income - Total segment and consolidated interest expense	(151,669)	(100,258)	(386,928)	(270,156)
Depreciation and amortization - Chinese Medicines	33,531	70,011	170,961	218,060
Depreciation and amortization - Stevioside	300,818	356,809	1,032,021	1,057,808
Depreciation and amortization - Total segment and consolidated depreciation and amortization	334,349	426,820	1,202,982	1,275,868
Loss before taxes and noncontrolling interest - Chinese Medicines	(6,964)	(38,147)	(521,873)	(188,043)
Loss before taxes and noncontrolling interest - Stevioside	(551,179)	(508,840)	(2,278,166)	(1,336,510)
Loss before taxes and noncontrolling interest - Corporate and other	(314,667)	(358,697)	(1,021,871)	(1,125,711)
Income (loss) before income taxes - Total segment and consolidated depreciation and amortization	$ (872,810)	$ (905,684)	$ (3,821,910)	$ (2,650,264)